Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages (Q39699893)

14 September 2017

title

Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages (English)

1 reference

14 September 2017

0 references

0 references

1 reference

Jianbo An

1 reference

14 September 2017

Toshiaki Nakajima

series ordinal

1 reference

14 September 2017

Keiji Kuba

series ordinal

1 reference

14 September 2017

Akinori Kimura

series ordinal

1 reference

14 September 2017

publication date

27 May 2010

1 reference

14 September 2017

published in

Hypertension Research

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

page(s)

831-835

1 reference

Atherosclerosis — An Inflammatory Disease

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Increased NADH-Oxidase–Mediated Superoxide Production in the Early Stages of Atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Local Overexpression of Toll-Like Receptors at the Vessel Wall Induces Atherosclerotic Lesion Formation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

https://api.crossref.org/works/10.1038%2FHR.2010.79

1 reference

7 January 2021

Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Demonstration of mRNA for five species of cytochrome P450 in human bone marrow, bone marrow-derived macrophages and human haemopoietic cell lines

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Multiple cytochrome P450-isoenzymes mRNA are expressed in dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Molecular determinants of crosstalk between nuclear receptors and toll-like receptors.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Hypo-responsiveness of interleukin-8 production in human embryonic epithelial intestine 407 cells independent of NF-kappaB pathway: new lessons from endotoxin and ribotoxic deoxynivalenol

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Novel AT(1) receptor-independent functions of losartan.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.79

7 January 2021

Identifiers

DOI

10.1038/HR.2010.79

1 reference

Dimensions Publication ID

14 September 2017

1027886971

0 references

1 reference